Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
GAITHERSBURG, Md., Aug. 30, 2016 -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be presenting at the 18th Annual Rodman & Renshaw Global Investment Conference to be held September 11 - 13, 2016 in New York, NY.
Bill Enright, Chief Executive Officer, is scheduled to present on Tuesday, September 13, 2016 at 10:50 AM ET.
About Altimmune
Altimmune is a clinical stage immunotherapeutic company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines. Using these technologies, Altimmune has developed three novel clinical stage product candidates that potentially represent an entirely new approach to harnessing the immune system.
The Company’s most advanced product candidate, NasoVAX, is a Phase 2-ready intranasally-delivered recombinant influenza vaccine offering broad and rapid protection with potential for significant advantages over traditional flu vaccines. The second most advanced product candidate, HepTcell, is being tested as an immunotherapy for patients chronically infected with hepatitis B and has the potential to provide a functional cure. With the support of the U.S. Biomedical Advanced Research and Development Authority, or BARDA, the Company is developing a third product candidate, NasoShield, a first-in-class anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. The Company intends to leverage the RespirVec and Densigen platforms to develop additional product candidates for a variety of indications.
Contacts: Bill Enright President and CEO Altimmune, Inc. Phone: 240-654-1450 Email: [email protected] Investor Relations Stephanie Carrington ICR, Inc. Phone: 646-277-1282 Email: [email protected]
